Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis-Reference-Cited by-同舟云学术

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Published:2018-12-11 Issue:3 Volume:26 Page:337-349
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Flamm Steven¹,Mutimer David²,Asatryan Armen³,Wang Stanley³,Rockstroh Jürgen⁴,Horsmans Yves⁵,Kwo Paul Y.⁶,Weiland Ola⁷^ORCID,Villa Erica⁸,Heo Jeong⁹,Gane Edward¹⁰,Ryder Stephen D.¹¹,Welzel Tania M.¹²,Ruane Peter J.¹³,Agarwal Kosh¹⁴^ORCID,Ng Teresa I.³,Xue Zhenyi³,Lovell Sandra S.³,Krishnan Preethi³,Kopecky‐Bromberg Sarah³,Trinh Roger³,Mensa Federico J.³,Wyles David L.¹⁵

Affiliation:

1. Northwestern Feinberg School of Medicine Chicago Illinois

2. Queen Elizabeth Hospital and NIHR Liver Biomedical Research Unit Birmingham UK

3. AbbVie Inc North Chicago Illinois

4. Universitätsklinikum Bonn Bonn Germany

5. Cliniques Universitaires Saint‐Luc UCL Brussels Belgium

6. Division of Gastroenterology and Hepatology Stanford University Palo Alto California

7. Karolinska University Hospital Huddinge at Karolinska Institute Stockholm Sweden

8. University of Modena and Reggio Emilia Modena Italy

9. Department of Internal Medicine College of Medicine Pusan National University and Medical Research Institute Pusan National University Hospital Busan Republic of Korea

10. Liver Unit Auckland City Hospital Auckland New Zealand

11. NIHR Nottingham Biomedical Research Centre and Nottingham University Hospitals NHS Trust Nottingham UK

12. JW Goethe University Hospital Frankfurt Germany

13. Ruane Medical & Liver Health Institute Los Angeles California

14. Institute of Liver Studies Kings College Hospital London UK

15. Denver Health Medical Center Denver Colorado

Funder

AbbVie

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology